ArriVent BioPharma, Inc.

AVBP Nasdaq SEC CIK 1868279
Follow ArriVent BioPharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $5M
Net income −$40.3M −15.3% vs same quarter last year
EPS, diluted −$0.81 +2.4% vs same quarter last year
Operating cash flow −$40.7M −13.7% vs same quarter last year
Net income by quarter
−$20.6M
−$64.4M
−$31.4M
−$35M
−$35.5M
−$43.3M
−$49.9M
−$40.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$200M−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$166.3M
FY24−$80.5M
FY23−$69.3M
FY22-